Protocol Ledger

NCT06717698 · Phase II · RECRUITING

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Interventional Phase II clinical trial protocol NCT06717698 sponsored by Novo Nordisk in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-02 Enrollment: 465 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06717698
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)465 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06717698
Protocol FieldVerified Registry Value
NCT IdentifierNCT06717698
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment465 participants (ESTIMATED)
Registered Start Date2024-12-02
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI